

Grifols announces a next-generation automated system to enhance efficiency and flexibility in transfusion medicine laboratories

- *Evanzys IH is an innovative modular system designed to streamline operations and reduce manual intervention in immunohematology sample processing*
- *The launch expands the company's portfolio of scalable blood typing solutions, helping healthcare professionals deliver safer and faster transfusion results while addressing the evolving needs of laboratories*
- *With this new platform, Grifols is taking another step toward the automated transfusion medicine laboratory of the future*

Barcelona, Spain, June 22, 2026 – Grifols (MCE:GRF, MCE:GRF. P, NASDAQ:GRFS), a global healthcare company and leader in plasma-derived medicines and innovative diagnostic solutions, today announced the launch of Evanzys IH, a next-generation automated system designed to enhance laboratory efficiency and flexibility in the analysis of immunohematology samples. The announcement was made during the opening of the International Society of Blood Transfusion (ISBT) Congress, which is being held in Kuala Lumpur (Malaysia) through June 24.

Evanzys IH is an innovative, modular, fully automated, track-enabled system developed to optimize laboratory operations, reduce manual intervention and support healthcare professionals in delivering safer and faster transfusion results. With this launch, Grifols further strengthens its existing immunohematology portfolio, including Erytra and Erytra Eflexis, while responding to laboratories' growing demand for scalable, connected and future-ready workflows.

"Evanzys IH represents a major milestone in our commitment to advancing innovation in transfusion medicine. With this new modular, track-enabled solution - the most innovative platform in the field - we are empowering laboratories to meet increasing automation demands while upholding the highest standards of quality, safety and efficiency", said Antonio Martínez, president of Grifols Diagnostic.

The launch of Evanzys IH, which expands Grifols' portfolio of blood typing solutions, is yet another example of the company's investment in R&D to develop cutting-edge diagnostic technologies. These innovations support the analysis of millions of donor and patient samples each year and reinforce Grifols' position as a global leader in blood screening and typing solutions.

In addition to this launch, the company is showcasing its latest innovations in immunohematology and donor screening at ISBT 2026, including Total Lab Automation (TLA) capabilities, advanced automation and digital connectivity. As part of the EVANZCare experience, customers benefit from a broader ecosystem of services, resources and expertise designed to strengthen long-term partnerships and support laboratory success. This approach reflects Grifols' commitment to delivering value beyond products alone. These integrated solutions represent a significant step toward the future of transfusion medicine by enabling end-to-end workflow automation—from sample handling to results management—with full traceability and real-time performance insights.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Phone: +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

investors@grifols.com – inversores@grifols.com

sustainability@grifols.com – sostenibilidad@grifols.com

Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.